Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
Summary
The purpose of this phase I trial is to evaluate the safety and feasibility of nab-paclitaxel in combination with low dose escalated radiation therapy in patients with pancreatic cancer.
General Information
NCT#: NCT02207465
Study ID: UPCC 32213
Trial Phase: Phase I
Trial Sponsor: University of Pennsylvania Abramson Cancer Center
Therapies Used in This Trial: Nab-paclitaxel, Intensity modulated radiation therapy (IMRT), Proton Radiation